EMD SERONO RESEARCH & DEVELOPMENT INSTITUTE, INC.

ACTIVE

45 Middlesex Tpke, Billerica, Massachusetts, United StatesSubsidiary

Also known as:

emd srdi

Part of MERCK KGAA

Clinical Trials

10 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

42.7%

Phase 2

29.2%

Phase 3

19.1%

Not Applicable

1.1%

Phase 4

1.1%

Trial Status Distribution

Active, not recruiting

7.9%

Completed

51.7%

Not yet recruiting

3.4%

Recruiting

7.9%

Terminated

27.0%

Withdrawn

2.3%

Clinical Trials

Trials sponsored by this organization (89)

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

Phase 3

Recruiting

interventional

May 20261,020 participants

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Phase 3

Recruiting

interventional

Apr 2026202 participants

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Phase 3

Not yet recruiting

interventional

Mar 2026202 participants

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Phase 3

Not yet recruiting

interventional

Mar 2026202 participants

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Phase 3

Recruiting

interventional

Mar 2026202 participants

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Phase 1

Recruiting

interventional

Feb 2026138 participants

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

Phase 1

Recruiting

interventional

Oct 202577 participants

A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

Phase 1

Completed

interventional

Jul 202555 participants

Page 1 of 12

Approvals

No approval data available

News

No news articles found

Back to Organizations